Correspondence 0001193125-24-069271 from Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc.
Date: March 15, 2024 · CIK: 0001855175 · Accession: 0001193125-24-069271
AI Filing Summary & Sentiment
Letter
Via EDGAR Division of Corporation Finance Attention: Daniel Crawford Re: Contineum Therapeutics, Inc. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted February 15, 2024 CIK No. 0001855175
Dear Mr. Crawford:
Contineum Therapeutics, Inc. (the “Company”) has electronically filed via EDGAR its registration statement on Form S-1 (the “Registration Statement”), together with certain exhibits thereto.
On behalf of the Company, this letter responds to the comments set forth in the letter to the Company dated February 23, 2024 from the staff of the Securities and Exchange Commission (the “Staff”). For your convenience, we have repeated and numbered the comments from the February 23, 2024 letter in bold italicized print, and the Company’s responses are provided below each comment. Page references in the text of this response letter correspond to the page numbers of the Registration Statement. Capitalized terms used but not defined herein are used herein as defined in the Registration Statement.
Securities and Exchange Commission
March 15, 2024
Page 2
Amendment No. 2 to Draft Registration Statement on Form S-1
Business
Our PIPE-791 Phase 1 Healthy Volunteer Trial, page 122
1. We note the newly included statement on page 123 that the primary and secondary objectives were “successfully characterized.” Please revise to clarify whether this is intended to mean that the primary and secondary objectives were met.
RESPONSE TO COMMENT 1:
The Company acknowledges the Staff’s comment and has revised the disclosure on page 122 of the Registration Statement to clarify that the trial met the primary and secondary objectives.
Securities and Exchange Commission
March 15, 2024
Page 3
Please do not hesitate to contact the undersigned at (858) 436-8046 or ryangunderson@gunder.com if you have any questions or would like additional information regarding this matter.
Very truly yours,
GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP SILICON VALLEY ANN ARBOR AUSTIN BEIJING BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO SÃO PAULO SINGAPORE March 15, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Daniel Crawford Laura Crotty Ibolya Ignat Kevin Juhar Re: Contineum Therapeutics, Inc. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted February 15, 2024 CIK No. 0001855175 Dear Mr. Crawford: Contineum Therapeutics, Inc. (the “Company”) has electronically filed via EDGAR its registration statement on Form S-1 (the “Registration Statement”), together with certain exhibits thereto. On behalf of the Company, this letter responds to the comments set forth in the letter to the Company dated February 23, 2024 from the staff of the Securities and Exchange Commission (the “Staff”). For your convenience, we have repeated and numbered the comments from the February 23, 2024 letter in bold italicized print, and the Company’s responses are provided below each comment. Page references in the text of this response letter correspond to the page numbers of the Registration Statement. Capitalized terms used but not defined herein are used herein as defined in the Registration Statement. Securities and Exchange Commission March 15, 2024 Page 2 Amendment No. 2 to Draft Registration Statement on Form S-1 Business Our PIPE-791 Phase 1 Healthy Volunteer Trial, page 122 1. We note the newly included statement on page 123 that the primary and secondary objectives were “successfully characterized.” Please revise to clarify whether this is intended to mean that the primary and secondary objectives were met. RESPONSE TO COMMENT 1: The Company acknowledges the Staff’s comment and has revised the disclosure on page 122 of the Registration Statement to clarify that the trial met the primary and secondary objectives. Securities and Exchange Commission March 15, 2024 Page 3 Please do not hesitate to contact the undersigned at (858) 436-8046 or ryangunderson@gunder.com if you have any questions or would like additional information regarding this matter. Very truly yours, GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP By: /s/ Ryan J. Gunderson Name: Ryan J. Gunderson cc: Carmine Stengone, Chief Executive Officer and President, Contineum Therapeutics, Inc. Peter T. Slover, Chief Financial Officer, Contineum Therapeutics, Inc. Jeffrey Thacker, Partner, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Frank F. Rahmani, Sidley Austin LLP Samir A. Gandhi, Sidley Austin LLP J. Carlton Fleming, Sidley Austin LLP